» Articles » PMID: 29141842

Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation)

Abstract

Background: It is unclear how frequently patients with atrial fibrillation receive guideline-concordant (GC) care and whether guideline concordance is associated with improved outcomes.

Methods And Results: Using data from ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), we determined how frequently patients received care that was concordant with 11 recommendations from the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society atrial fibrillation guidelines pertaining to antithrombotic therapy, rate control, and antiarrhythmic medications. We also analyzed the association between GC care and clinical outcomes at both the patient level and center level. A total of 9570 patients were included. The median age was 75 years (interquartile range, 67-82), and the median CHADS-VASc score was 4 (interquartile range, 3-5). A total of 5977 patients (62.5%) received care that was concordant with all guideline recommendations for which they were eligible. Rates of GC care were higher in patients treated by providers with greater specialization in arrhythmias (60.0%, 62.4%, and 67.0% for primary care physicians, cardiologists, and electrophysiologists, respectively; <0.001). During a median of 30 months of follow-up, patients treated with GC care had a higher risk of bleeding hospitalization (hazard ratio=1.21; =0.021) but a similar risk of death, stroke, major bleeding, and all-cause hospitalization.

Conclusions: Over a third of patients with atrial fibrillation in this large outpatient registry received care that differed in some respect from guideline recommendations. There was no apparent association between GC care and improved risk-adjusted outcomes.

Citing Articles

Phenotypes of Patients with Direct Oral Anticoagulant (DOAC) Underdosing in Atrial Fibrillation: Results from the ARENA Registry.

Brockmuller C, Meid A, Senges J, Hochadel M, Haefeli W, Stoll F Clin Drug Investig. 2024; 45(1):29-43.

PMID: 39666256 PMC: 11757868. DOI: 10.1007/s40261-024-01411-w.


Designing and validating a clinical decision support algorithm for diabetic nephroprotection in older patients.

Alsalemi N, Sadowski C, Elftouh N, Kilpatrick K, Houle S, Leclerc S BMJ Health Care Inform. 2024; 31(1).

PMID: 39209331 PMC: 11367403. DOI: 10.1136/bmjhci-2023-100869.


Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator.

Zylla M, Wolfes J, Schleberger R, Lawin D, Kieser M, Reinke F Clin Res Cardiol. 2024; 113(6):933-941.

PMID: 38372753 PMC: 11108879. DOI: 10.1007/s00392-024-02394-6.


Anti-arrhythmic drugs in atrial fibrillation: tailor-made treatments.

Capucci A, Stronati G, Guerra F Eur Heart J Suppl. 2023; 25(Suppl C):C12-C14.

PMID: 37125269 PMC: 10132592. DOI: 10.1093/eurheartjsupp/suad033.


Associations of Community and Individual Social Determinants of Health With Medication Adherence in Patients With Atrial Fibrillation: A Retrospective Cohort Study.

Boyd L, Colavecchia A, Townsend K, Kmitch L, Broder L, Hegeman-Dingle R J Am Heart Assoc. 2023; 12(8):e026745.

PMID: 37026552 PMC: 10227243. DOI: 10.1161/JAHA.122.026745.